secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K/A
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001437749-24-030345
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences discloses CEO Richard Barry compensation: $675k base, 600k options at $27.42
--------------------------------------------------------------------------------

- Base salary $675,000, retroactive to July 15, 2024; annual bonus target 60% of base salary.
- Stock option award of 600,000 shares at $27.42 exercise price; vests 25% annually starting July 15, 2025.
- Termination without cause or for good reason triggers 12-month base salary continuation plus health benefits.
- Options granted under 2018 Omnibus Equity Incentive Plan; change-in-control triggers same severance.
- Agreement includes standard confidentiality, non-disclosure, and mandatory arbitration provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924030345/0001437749-24-030345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774924030345/sava20240930_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer